The ACACA antibody is designed to detect acetyl-CoA carboxylase alpha (ACACA), a critical enzyme in fatty acid biosynthesis. ACACA catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis, and is regulated by hormonal and nutritional signals. It exists in two isoforms (ACC1 and ACC2), with ACC1 primarily localized in the cytoplasm and involved in lipogenesis, while ACC2 is mitochondrial-associated and regulates fatty acid oxidation. Dysregulation of ACACA is linked to metabolic disorders (e.g., obesity, diabetes) and cancers, where overexpression promotes tumor growth by fueling membrane biosynthesis and energy storage. The ACACA antibody is widely used in research to study its expression, post-translational modifications (e.g., phosphorylation at Ser79), and interactions in cellular metabolism. It is validated in applications like Western blotting, immunohistochemistry, and immunofluorescence, often utilizing tissues or cell lines with high metabolic activity (e.g., liver, adipose, cancer cells). Researchers also employ this antibody to explore therapeutic targeting of ACACA in metabolic syndromes and oncology. Specificity is confirmed via knockout controls or siRNA knockdown. Commercial variants may differ in host species (rabbit, mouse), clonality (monoclonal/polyclonal), and epitope recognition.